Yes, several alternatives to Dupixent exist, and the right one depends on which condition you’re treating. Dupixent is approved for atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, and prurigo nodularis, and each condition has its own set of alternative therapies ranging from other biologics to oral medications to topical treatments.
Alternatives for Atopic Dermatitis
Atopic dermatitis is the most common reason people take Dupixent, and it’s also the condition with the most alternatives. Current guidelines recommend several options alongside topical therapy for moderate-to-severe eczema that hasn’t responded to creams and ointments alone: other biologics (tralokinumab, nemolizumab), oral JAK inhibitors (upadacitinib, abrocitinib, baricitinib), phototherapy, and older immunosuppressants like cyclosporine and methotrexate.
Other Biologics
Tralokinumab (brand name Adbry) is the closest alternative to Dupixent. Both are injectable biologics, but they work slightly differently. Dupixent blocks a receptor involved in two inflammatory signals (IL-4 and IL-13), while tralokinumab targets only IL-13. For many patients the results are comparable, though Dupixent has more long-term data behind it. One practical difference: tralokinumab is currently approved only for adults (ages 18 and up in the U.S., 12 and up in Europe), while Dupixent is approved down to 6 months of age.
Nemolizumab works through a completely different pathway, blocking the signal (IL-31) most directly responsible for itch. It’s a newer option that may be particularly useful if intense itching is your primary symptom.
JAK Inhibitors (Pills)
If you’d rather take a pill than give yourself injections, JAK inhibitors are the main alternative. Upadacitinib (Rinvoq) and abrocitinib (Cibinqo) are both oral tablets taken daily. They work by blocking a broader range of inflammatory pathways than biologics do, which can translate to faster results. Some patients notice improvement within the first week or two.
The tradeoff is safety. The FDA requires JAK inhibitors to carry boxed warnings about increased risks of serious heart events, blood clots, cancer, and death. These warnings were driven primarily by a large safety trial of a related drug (tofacitinib) in rheumatoid arthritis patients, and the FDA extended the warnings to upadacitinib and baricitinib as a precaution because they share the same mechanism. The risks are highest in people who smoke, have cardiovascular risk factors, or have a history of cancer. Dupixent does not carry these warnings, which is one reason many dermatologists try it first.
Because of these safety concerns, JAK inhibitors are generally positioned for patients who haven’t responded well to Dupixent or other biologics, rather than as a first-line systemic choice.
Topical JAK Inhibitors
Ruxolitinib cream (Opzelura) is a topical JAK inhibitor approved for mild-to-moderate atopic dermatitis in patients 12 and older. It fills a different niche than Dupixent. If your eczema is limited in area and hasn’t responded well to standard prescription creams like topical steroids or calcineurin inhibitors, ruxolitinib may be enough on its own. For more widespread or severe disease, it’s sometimes used alongside a systemic treatment. It won’t replace Dupixent for moderate-to-severe cases, but it can be a reasonable step before escalating to systemic therapy.
Older Systemic Options
Cyclosporine and methotrexate have been used for severe eczema for decades. They’re less targeted than newer options and come with their own side-effect profiles, including kidney concerns with cyclosporine and liver monitoring with methotrexate. They’re typically considered when newer therapies aren’t accessible or affordable, or as a bridge while waiting for a biologic to take effect. Phototherapy (controlled UV light exposure, usually done in a clinic two to three times per week) is another established option that avoids systemic medication entirely.
Alternatives for Nasal Polyps
For chronic rhinosinusitis with nasal polyps, two other biologics are approved: omalizumab (Xolair) and mepolizumab (Nucala). Both have been shown to reduce nasal polyp size, improve congestion, and reduce the need for surgery or oral steroids. Omalizumab targets a different part of the immune system (IgE, the antibody involved in allergic reactions), while mepolizumab blocks a signal (IL-5) that drives eosinophilic inflammation. Your doctor’s choice between these typically depends on your specific inflammatory profile, whether you have coexisting asthma, and which biologic your insurance covers.
Alternatives for Eosinophilic Esophagitis
For eosinophilic esophagitis (EoE), the landscape looks quite different. Dupixent was a breakthrough for this condition, but several other approaches can be effective.
Swallowed topical corticosteroids are the most established alternative. These are steroid formulations designed to coat the esophagus rather than reach the lungs or stomach. An oral budesonide suspension (Eohilia) was FDA-approved in early 2024 for patients ages 11 to 55, and a budesonide dissolving tablet (Jorveza) has been available in Europe since 2017. In clinical studies, patients taking swallowed topical steroids were about three times more likely to see symptom improvement compared to placebo, and histologic remission rates were dramatically higher.
Proton pump inhibitors (PPIs) like omeprazole are used off-label but can be surprisingly effective. A meta-analysis of 33 studies found that PPIs achieved histologic remission in about 50% of patients and symptom improvement in roughly 61%. Around 73% of patients who responded maintained remission after at least a year when their dose was tapered to the lowest effective amount. Twice-daily dosing tends to work better than once daily.
Dietary elimination is another well-established approach, typically removing common trigger foods (often milk, wheat, eggs, soy, nuts, and seafood) and reintroducing them one at a time. This requires significant commitment and close monitoring with repeat endoscopies, but some patients prefer avoiding medication altogether.
Alternatives for Prurigo Nodularis
Prurigo nodularis has historically been difficult to treat, and Dupixent was one of the first therapies to show strong results in clinical trials. Nemolizumab received European approval for this condition in 2025 and is the most promising biologic alternative, showing rapid improvement in both itch and lesion counts.
Traditional options include topical steroids, calcineurin inhibitors, phototherapy, and systemic immunosuppressants like cyclosporine, methotrexate, and thalidomide. These work for some patients but often provide only partial relief. JAK inhibitors, particularly upadacitinib, have shown efficacy in treatment-resistant cases and are being studied more formally. Several other targeted therapies are in development, including drugs that block different itch and inflammatory pathways.
How Cost Compares
Dupixent’s list price is a major reason people search for alternatives. Without insurance, all the biologic and JAK inhibitor options are expensive. Adbry costs roughly $2,085 per dose (covering two prefilled syringes), while Rinvoq runs about $6,934 for a 30-day supply of tablets at the 15 mg strength. Dupixent itself lists around $3,500 per month without coverage. The actual amount you pay depends heavily on your insurance plan, and all three manufacturers offer copay assistance programs that can reduce out-of-pocket costs significantly for eligible patients.
Older systemic options like cyclosporine and methotrexate are dramatically cheaper, often costing under $100 per month as generics. PPIs for EoE are similarly affordable. If cost is the primary driver, these older treatments are worth discussing with your provider, keeping in mind they require more frequent lab monitoring.
Choosing the Right Alternative
The best alternative depends on several factors: which condition you’re treating, how severe it is, your age, whether you prefer injections or pills, your comfort level with the safety profiles, and what your insurance will cover. JAK inhibitors offer the convenience of a daily pill and sometimes faster results, but carry more serious safety warnings. Other biologics like tralokinumab offer a similar treatment experience to Dupixent with a slightly different mechanism that may work when Dupixent hasn’t. For milder disease or localized symptoms, topical options or phototherapy may be enough to avoid systemic treatment entirely.
If you’re considering switching because Dupixent isn’t working well enough, it’s worth knowing that JAK inhibitors block a wider range of inflammatory signals than any single biologic. That broader coverage is why some patients who don’t fully respond to Dupixent do better on a JAK inhibitor, and vice versa.